Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

NCT05481645 on ClinicalTrials.gov Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (industry) Started 2022-08-26 Terminated

Riskier than 41% of active trials

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (1,304 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Terminated on 2025-11-30, after 2022-08-26 start.

Reason given by the sponsor: “business”

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: transplantbonesubjectsubjectscancer
Phrases that lowered it: efficacy andand safetymedical historysafety ofthe efficacy
Accepts healthy volunteers: No (raises risk) · Who can join
Phase: 2 (raises risk) · Design
Has a data monitoring committee: not given (lowers risk) · Design
Design: parallel (raises risk) · Design
Drug's FAERS reports with a death: 17.4% (lowers risk) · Drug's FDA history
Trials the sponsor started in the prior 2 years: 70 (lowers risk) · Sponsor's track record
Sponsor's past termination rate: 8.1% (raises risk) · Sponsor's track record
Disease area, cancer: No (lowers risk) · Disease area
Minimum age: 18 (raises risk) · Who can join
Number of arms: 3 (lowers risk) · Design
Sponsor type: industry (lowers risk) · Sponsor's track record
Primary purpose: treatment (raises risk) · Design
Drug's FAERS reports before start: 362603 (lowers risk) · Drug's FDA history
Drugs with FDA adverse-event history: 5 (lowers risk) · Drug's FDA history
Drug's FAERS reports marked serious: 91.4% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 2
Number of arms: 3 (typical: 2)
Allocation: randomized
Design: parallel
Primary purpose: treatment
Blinding: none
Has a data monitoring committee: not given (typical: 56% yes)
Responsible party: sponsor
Collaborators: 0
Keywords listed: 0 (typical: 1)

Who can join

Minimum age: 18
Maximum age: not given (typical: 71)
Sex: female (typical: all)
Accepts healthy volunteers: No (typical: 9% yes)

Sponsor's track record

Sponsor type: industry (typical: academic or other)
Sponsor's past trials: 37 (typical: 32)
Sponsor's past termination rate: 8.1% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 70 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 5 (typical: 1)
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 362603 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 37942 (typical: 412.5)
Drug's FAERS reports marked serious: 91.4% (typical: 85.6%)
Drug's FAERS reports with a death: 17.4% (typical: 15.9%)

Disease area and drugs

Disease areas: none of the 14 tracked areas
Drugs matched to FDA substances: carboplatin, docetaxel, doxorubicin, gemcitabine, paclitaxel

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT05834543 · started 2023 · scored riskier than 39% of active trials terminated
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer NCT06321068 · started 2024 · scored riskier than 71% of active trials terminated
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma NCT05496569 · started 2022 · scored riskier than 58% of active trials terminated
Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma NCT03829969 · started 2019 · scored riskier than 59% of active trials completed
An Phase I Study of YY001 in Patients with Advanced Solid Tumors NCT06228846 · started 2022 · scored riskier than 22% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.